Medios AG Appoints Thomas Meier as New CEO to Drive European Specialty Pharma Growth

The Supervisory Board of Medios AG has appointed Thomas Meier as a member of the Executive Board with effect from February 1, 2026, and designated him the new Chief Executive Officer of the Company. He succeeds Matthias Gaertner, who will remain in office until December 31, 2025. This leadership transition comes at a critical juncture as Medios positions itself for expanded growth in the competitive European pharmaceutical landscape.

Thomas Meier brings substantial international experience to his new role, having served as CEO of Swiss CDMO company Bachem Holding AG since 2020. His background includes previous roles as Chief Operations Officer on the Executive Board of Bachem and Head of Manufacturing at Peninsula Laboratories in San Carlos, California from 2001 to 2004. This diverse experience across different pharmaceutical sectors and geographic markets positions him well to lead Medios through its next development phase.

Dr. Yann Samson, Chairman of the Supervisory Board of Medios AG, emphasized the strategic importance of this appointment, stating that Meier represents an internationally experienced leader with a proven track record of capital-efficient, profitable growth. The Supervisory Board expressed confidence that Meier's entrepreneurial spirit, expertise and leadership will contribute significantly to achieving the company's ambitious goals and sustainably increasing value for shareholders, partners, and customers. Simultaneously, the Board extended sincere thanks to outgoing CEO Matthias Gaertner for his outstanding work and commitment over the past ten years, during which he decisively influenced Medios's growth and success.

Thomas Meier expressed enthusiasm for his new role, noting his anticipation of leading Medios into its next phase of development. He committed to working collaboratively with Executive Board colleagues and the entire Medios team to consistently develop the company's successful strategy and sustainably expand Medios's position in the European Specialty Pharma market. This leadership change occurs as Medios prepares for several important financial events, including the Quarterly Statement as of September 30, 2025 on November 11, participation in the mwb inspired Conference in Hamburg on November 12, and the Berenberg European Conference at Fairmont Windsor Park, GB on December 04.

The appointment signals Medios's continued focus on strengthening its position as a leading provider of Specialty Pharma in Europe. With operations spanning Germany, the Netherlands, Belgium and Spain, the company supports key partners in the supply chain with innovative solutions and intelligent services. Medios has established itself as a pioneer in individualized medicine, working to make the most innovative therapies accessible through partnerships with pharmacies, specialist practices and pharmaceutical companies. As Germany's first listed specialty pharmaceutical company, Medios AG maintains its shares on the regulated market of the Frankfurt Stock Exchange (Prime Standard) within the SDAX selection index. Additional information about the company's approach to individualized medicine is available at https://app.medios.group/en/individualizedmedicine while corporate details can be found at https://www.medios.group.